First, it benefits the patient: non-adherence accounts for an estimated 125,000 preventable deaths per year in the US, many from controllable conditions such as HIV and type 2 diabetes, plus at least $100bn in healthcare costs. Second, private lapses matter for public health: drug-resistant strains of tuberculosis have emerged triumphant from half-finished treatment courses.